Vycellix, Avectas partner for product development

By The Science Advisory Board staff writers

March 26, 2020 -- Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

The companies will partner on the use of Vycellix's RNA immunomodulator VY-M for immunodiscovery cell and gene therapy with Avectas' Solupore cell engineering platform to address the current limitations of cell-based therapies and the need to accelerate manufacturing processes, reduce manufacturing costs, and improve patient outcomes.

Vycellix and Avectas also are currently collaborating with NextGenNK, a newly established competence center for the development of next-generation natural killer cell-based cancer immunotherapies based at Karolinska Institutet in Stockholm, Sweden.


Copyright © 2020 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter